"If tragedy never entered our lives, we wouldn't appreciate the magic." - Nikki Rowe
I have had a few questions around mid-cap oncology concern Exelixis (EXEL) recently as the shares got a boost from the buyout of ArQule (ARQL) to start the week. A full investment analysis is presented in the paragraphs below as we revisit this name.
Company Overview
Exelixis is an Alameda, California-based oncology-oriented biotechnology company that focuses on forms of cancer that are especially challenging to treat. Leveraging research on model system genetics, the company has developed